{"id":5250,"date":"2021-03-01T01:21:55","date_gmt":"2021-03-01T09:21:55","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=5250"},"modified":"2021-03-02T01:30:34","modified_gmt":"2021-03-02T09:30:34","slug":"antibody-response-to-first-bnt162b2-dose-in-previously-sars-cov-2-infected-individuals","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/03\/01\/antibody-response-to-first-bnt162b2-dose-in-previously-sars-cov-2-infected-individuals\/","title":{"rendered":"Antibody Response to First BNT162b2 Dose in Previously SARS-CoV-2-Infected Individuals"},"content":{"rendered":"<ul>\n<li>A nested case-control study of 51 health care workers found that anti-S titers 19-29 days after the first dose of the Pfizer\/BioNTech vaccine were comparable to peak titers after natural infection. Among those with a previous SARS-CoV-2 infection, vaccination increased anti-S titers more than 140-fold from peak pre-vaccine levels. Prior infection was determined by positive detection of antibodies against the SARS-CoV-2 nucleocapsid or the receptor binding domain of the SARS-CoV-2 S1 subunit of the spike protein.<\/li>\n<\/ul>\n<p><i>Manisty et al. (Feb 26, 2021). Antibody Response to First BNT162b2 Dose in Previously SARS-CoV-2-Infected Individuals. The Lancet. <\/i><a href=\"https:\/\/doi.org\/10.1016\/S0140-6736(21)00501-8\">https:\/\/doi.org\/10.1016\/S0140-6736(21)00501-8<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A nested case-control study of 51 health care workers found that anti-S titers 19-29 days after the first dose of the Pfizer\/BioNTech vaccine were comparable to peak titers after natural infection. Among those with a previous SARS-CoV-2 infection, vaccination increased anti-S titers more than 140-fold from peak pre-vaccine levels. Prior infection was determined by positive&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/03\/01\/antibody-response-to-first-bnt162b2-dose-in-previously-sars-cov-2-infected-individuals\/\">Read more<\/a><\/div>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[33],"topic":[31],"class_list":["post-5250","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-vaccines","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/5250","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=5250"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/5250\/revisions"}],"predecessor-version":[{"id":5251,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/5250\/revisions\/5251"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=5250"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=5250"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=5250"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=5250"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}